Jefferson researchers show chemotherapy and radiation together extend lung cancer patients' lives

November 09, 2007

(PHILADELPHIA) Chemotherapy given at the same time as radiation therapy can help patients with a certain type of lung cancer live nearly 50 percent longer than they might have otherwise if the same treatment was given differently, according to an international team's analysis of several trial results.

Walter Curran Jr., M.D., professor and chair of Radiation Oncology at Jefferson Medical College of Thomas Jefferson University and Jefferson's Kimmel Cancer Center in Philadelphia, led one of six trials comparing the effectiveness of giving chemotherapy at the same time as radiation therapy versus giving radiation first, followed later by chemotherapy, to treat locally advanced non-small cell lung cancer (NSCLC).

According to Dr. Curran, there had been some controversy over whether simultaneous administration of chemotherapy and radiation for such cases was better than sequential delivery. In the United States, chemotherapy and radiation together have become the standard, whereas in other areas, such as Europe, for example, this has not been the case.

To try to resolve the matter, the International NSCLC Collaborative Group examined the results of more than 1,200 patients from six trials. The researchers found that the five-year survival rate was 10.6 percent with sequential therapy, while 15.1 percent with concurrent treatment. Dr. Curran presented the results recently at the meeting of the American Society for Therapeutic Radiology and Oncology in Los Angeles.

"That means a relative increase of nearly 50 percent," notes Dr. Curran, who led the Radiation Therapy Oncology Group (a Philadelphia-based cooperative clinical trials organization) trial. "We've demonstrated that the magnitude of benefit is observable in many studies, regardless of the regimen. I think it will be as persuasive as any data that this will change not only the tumor control rate but the chance for a long-term cure."

Dr. Curran explains that the only difference in the two treatments is that radiation is begun at another time. The drugs and radiation techniques are the same. "You're changing the first day of radiation from day 40 to day one, for example, and as a result, are changing the number of five-year survivors by between 40 percent and 50 percent," he says. According to these findings, theoretically, if there were 50,000 patients, approximately 5,000 who received sequential therapies would be alive in five years, and with concurrent, about 7,500."It is a new standard of care," he says about the results. "It's relatively broadly adopted in this country, but across the world, it hasn't been. This will be a very persuasive argument."
-end-


Thomas Jefferson University

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.